Treatment of obsessive-compulsive disorders with 5-HT.sub.2 antagonists
US5618824A · kind A · utility
24Cited by
5References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 1994 |
| Grant date | Apr 8, 1997 |
| Priority date | — |
| Expiry date | Mar 9, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to 5-HT.sub.2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol which is a member of a class of 5-HT.sub.2 antagonists known as N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5-HT.sub.2 receptor site.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.